Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384687 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBHTTCA1CA2 | |
| SCHEMBL13384759 | 0.85 | ALDH1A1 (0.51) | ALDH1A1POLBHTTCA1CA2 | |
| SCHEMBL13384763 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBHTTCA1CA2 | |
| SCHEMBL26127364 | 0.84 | HPGD (0.48) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL30608109 | 0.84 | HPGD (0.48) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL13384745 | 0.84 | ALDH1A1 (0.50) | ALDH1A1POLBHTTCA1CA2 | |
| SCHEMBL13384746 | 0.79 | ALDH1A1 (0.46) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL3107098 | 0.75 | ATM (0.55) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL29525910 | 0.75 | ATM (0.55) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL13384761 | 0.75 | ALDH1A1 (0.64) | ALDH1A1POLBMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| WO-2008037784-A1 | QUINOLINONE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | CHRM1, CYP2C8, CCR8 | ALDH1A1 784/4885POLB 3018/4885HTT 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.